The AI Mirror: “take that small hit, and you’ll be fine”

I published the post below last month, which resulted in an invitation to speak with DeAnn and Craig Knighton on their podcast, Recovery Discovery. It was a fun conversation and I thought I'd share that with you here. https://open.spotify.com/episode/5YYECT2NeBogNVSehvQm6w?si=auerM5dAQfenEQ6Xn_zN5w I also want to share a couple of things that have come up since the interview. … Continue reading The AI Mirror: “take that small hit, and you’ll be fine”

“further research is needed to improve treatment retention”

Kleinman RA, Kurdyak P. Duration of Methadone and Buprenorphine-Naloxone Treatment. JAMA Network Open. 2025;8(7):e2518389. doi:10.1001/jamanetworkopen.2025.18389 An eye-popping article was just published in JAMA about trends in the duration of methadone and buprenorphine treatment in Ontario, Canada, including more than 72,000 new recipients of opioid agonist treatments. The median duration of buprenorphine treatment declined by 25%, … Continue reading “further research is needed to improve treatment retention”

The AI Mirror: “take that small hit, and you’ll be fine”

A few weeks ago, an article in Futurism described a troubling exchange between an AI chatbot and a user identifying as Pedro, a person identified as having methamphetamine addiction seeking advice about how to make it through his work shifts when he's feeling exhausted and has abstained from methamphetamine for 3 days. The chatbot encourages … Continue reading The AI Mirror: “take that small hit, and you’ll be fine”

3-in-4 current fentanyl users started with prescription opioids

For years, many experts have "well, actually-ed", arguing that prescribing patterns had little to do with the opioid crisis. Of course, the opioid crisis is a complex and wicked problem, but we are poorly served by experts who scold the public and tell us not to believe our lying eyes. JAMA Health Forum provides some … Continue reading 3-in-4 current fentanyl users started with prescription opioids

Medications for Opioid Use Disorder: Enhancing Retention to Achieve Longterm Remission and Recovery

A newly published monograph "addresses the challenges of achieving long-term stable (OUD) remission and recovery, and, more specifically, the related challenges involved in adherence and retention within the pharmacotherapeutic treatment of OUD." This document is a critical step toward understanding what medication can and cannot achieve for which patients under what circumstances. This right-sizing of … Continue reading Medications for Opioid Use Disorder: Enhancing Retention to Achieve Longterm Remission and Recovery